Denali Therapeutics Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Denali Therapeutics Inc. (DNLI) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 28.50 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 30.00M shares, a 9.49% increase year-over-year.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 27.40M shares, a 12.30% increase year-over-year.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 24.40M shares, a 14.02% increase year-over-year.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 21.40M shares, a 16.30% increase year-over-year.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 28.80M shares, a 24.14% increase from fiscal 2024.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 23.20M shares, a 13.17% increase from fiscal 2023.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 20.50M shares, a 12.64% increase from fiscal 2022.
- Denali Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 18.20M shares, a 10.30% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 28.50M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 30.00M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 28.80M shares 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | 27.40M shares 10-Q · filed 2025-11-06 | |||||||
| 2025-06-30 | 28.50M shares 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | 27.40M shares 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | 23.20M shares 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | 22.70M shares 10-Q · filed 2025-11-06 | |||||||
| 2024-06-30 | 23.30M shares 10-Q · filed 2025-08-11 | |||||||
| 2024-03-31 | 24.40M shares 10-Q · filed 2025-05-06 | |||||||
| 2023-12-31 | 20.50M shares 10-K · filed 2026-02-26 | |||||||
| 2023-09-30 | 20.70M shares 10-Q · filed 2024-11-06 | |||||||
| 2023-06-30 | 11.80M shares 10-Q · filed 2024-08-01 | |||||||
| 2023-03-31 | 21.40M shares 10-Q · filed 2024-05-07 | |||||||
| 2022-12-31 | 18.20M shares 10-K · filed 2025-02-27 | |||||||
| 2022-09-30 | 18.40M shares 10-Q · filed 2023-11-07 | |||||||
| 2022-06-30 | 18.40M shares 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | 18.40M shares 10-Q · filed 2023-05-08 | 18.40M shares 10-Q · filed 2022-05-05 | ||||||
| 2021-12-31 | 16.50M shares 10-K · filed 2024-02-28 | 16.47M shares 10-K · filed 2022-02-28 | ||||||
| 2021-09-30 | 16.50M shares 10-Q · filed 2021-11-04 | 16.50M shares 10-Q · filed 2022-11-03 | 16.50M shares 10-Q · filed 2021-11-04 | |||||
| 2021-06-30 | 16.70M shares 10-Q · filed 2021-08-04 | 16.70M shares 10-Q · filed 2022-08-08 | 16.70M shares 10-Q · filed 2021-08-04 | |||||
| 2021-03-31 | 17.02M shares 10-Q · filed 2022-05-05 | |||||||
| 2020-12-31 | 4.20M shares 10-K · filed 2023-02-27 | 4.17M shares 10-K · filed 2021-02-26 | ||||||
| 2020-09-30 | 15.95M shares 10-Q · filed 2021-11-04 | 15.95M shares 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | 16.02M shares 10-Q · filed 2021-08-04 | 16.02M shares 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | 16.17M shares 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | 12.80M shares 10-K · filed 2022-02-28 | |||||||
| 2019-09-30 | 12.82M shares 10-Q · filed 2020-11-05 | 12.82M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 12.87M shares 10-Q · filed 2020-08-07 | 12.87M shares 10-Q · filed 2020-08-07 | ||||||
| 2019-03-31 | 12.82M shares 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 10.43M shares 10-K · filed 2021-02-26 | |||||||
| 2018-09-30 | 10.74M shares 10-Q · filed 2019-11-06 | 10.74M shares 10-Q · filed 2019-11-06 | ||||||
| 2018-06-30 | 10.66M shares 10-Q · filed 2019-08-06 | 10.66M shares 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | 11.09M shares 10-Q · filed 2019-05-08 | |||||||
| 2017-12-31 | 9.50M shares 10-K · filed 2020-02-27 | |||||||
| 2017-09-30 | 67.98M shares 10-Q · filed 2018-11-08 | 67.98M shares 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | 68.21M shares 10-Q · filed 2018-08-09 | 68.21M shares 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | 68.59M shares 10-Q · filed 2018-05-11 | |||||||
| 2016-12-31 | 68.49M shares 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |